For the use of registered medical practitioner or hospital or laboratory only
Influvac Tetra more power with Broad protection
1. Macias A E et al. The disease burden of influenza beyond respiratory illness. Vaccine 2021;39;1:A6-A14
2. Fang Y A et al. Influenza Vaccination Reduces Hospitalization for Heart Failure in Elderly Patients with Chronic Kidney Disease: A Population-Based Cohort Study. Acta Cardiol Sin. 2016 May; 32(3): 290–298.
3. World Health Organization (WHO). Background Paper on Influenza Vaccines and Immunization. SAGE Working Group [Internet] [Cited 2019 Aug 2]. Available at: https://www.who.int/immunization/sage/meetings/2012/april/1 Background_Paper_Mar26_v13_cleaned.pdf.
4. Centers for Disease Control and Prevention. Quadrivalent Influenza Vaccine. [Internet] [Updated 2019 Nov 6] [Cited 2023 Jan 16]. Available at: https://www.cdc.gov/flu/prevent/quadrivalent.htm.
5. Shah R et al. Advantages of Subunit Influenza Vaccine: An Overall Perspective. AJPP. 2018; 1(5): 19-28.
6. Wood JM, Williams MS. History of inactivated Influenza vaccines. In: textbook of influenza. Oxford: Blackwell Science 1998, pp. 317-323.
7. Influvac Tetra PI, Data on file
8. Zuccotti GV, Fabiano V. Influvac, a trivalent inactivated subunit influenza vaccine. Expert Opin Bial Ther 2011;11(1):89-98.
Influvac Tetra is registered trademark of Abbott Biologicals B.V.
IND2267505 17 Mar 2023